LCS
HALO icon

Levin Capital Strategies’s Halozyme HALO Stock Holding History

Levin Capital Strategies’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-15,000
Closed -$119K – 320
2013
Q2 		$119K Buy
+15,000
New +$95.5K ﹤0.01% 312

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Levin Capital Strategies's HALO Position: Q3 2013 in Review

Levin Capital Strategies sold out of Halozyme (HALO) in Q3 2013, closing a stake of 15,000 shares — an estimated $119K sold.

Levin Capital Strategies first reported a position in HALO in Q2 2013 and held it in 1 quarter. The position peaked at $119K in Q2 2013. 110 funds tracked by Wall St. Rank hold HALO as of Q3 2013.

  • Levin Capital Strategies reported no remaining Halozyme position as of Q3 2013 after selling out during the quarter.
  • Levin Capital Strategies sold 15,000 Halozyme shares in Q3 2013, an estimated $119K.
  • Levin Capital Strategies first reported a position in Halozyme in Q2 2013 and held it in 1 quarter.
  • Levin Capital Strategies's Halozyme position peaked at $119K in Q2 2013.
  • 110 funds tracked by Wall St. Rank held Halozyme as of Q3 2013.

Based on Levin Capital Strategies's 13F filing for Q3 2013, filed 12 Nov 2013.